Abeona Therapeutics

Zevaskyn launched with a $3.1 million list price per treatment, supported by published coverage policies from all Medicaid programs and major commercial plans and by a permanent J‑code. Early net revenue per case of ~$2.4 million (Medicaid) suggests materially positive realized pricing even before a richer commercial mix.

Outcomes‑based features may limit extreme outliers but reinforce payer confidence. Relative to RDEB’s lifelong cost and burden, payer willingness looks durable if logistics and outcomes remain strong. Main constraints are the small TAM, outcomes safeguards, and competition from Vyjuvek that may set implicit reference values.